Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | APG-2575 + unspecified immune checkpoint inhibitor |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| APG-2575 | APG 2575|APG2575|Lisaftoclax | BCL2 inhibitor 29 | APG-2575 is a small molecule that inhibits BCL-2, potentially resulting in increased apoptosis and enhanced antitumor activity in combination with other agents (PMID: 32093809, PMID: 37074726). | |
| unspecified immune checkpoint inhibitor | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|